Our award-winning statistical and data experts have demonstrated leadership in rigorous study design, close client collaboration, and a strong track record for widely disseminated, impactful analyses. Pharmaceutical and device manufacturers rely on our research to support discussions with payers, providers, regulators, and policymakers to advance the use of data-driven decision making to improve outcomes and reduce healthcare costs. Our robust proprietary data asset, the MORE² Registry^®, strengthens our analyses by leveraging information from more than 63 billion medical events and 338 million unique patients across commercial, fee-for-service Medicare (100%), Medicare Part D (100%), Medicare Advantage, and managed Medicaid populations. We interpret the data based on real-world evidentiary health outcomes, focusing on comprehensive health economic insight to identify market gaps and revenue opportunities and demonstrate value-based benefits. Applying our proprietary data, we can track patients for a longer length of time across payer types; conduct time-to-event analysis using exact service dates; segment providers with identified NPI, name, and address; and link to external databases using deterministic (versus probabilistic) matching, including rich, granular social risk-factor, program evaluation, clinical trial, and benefit design and formulary data, as well as EHRs, health registries, and health risk assessments. Count on us to supplement your internal data.